CA Patent

CA2585482C — Treatment of short bowel syndrome patients with colon-in-continuity

Assigned to Shire NPS Pharmaceuticals Inc · Expires 2018-01-02 · 8y expired

What this patent protects

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with GLP-2 receptor agonist, such as teduglutide.

USPTO Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with GLP-2 receptor agonist, such as teduglutide.

Drugs covered by this patent

Patent Metadata

Patent number
CA2585482C
Jurisdiction
CA
Classification
—
Expires
2018-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Shire NPS Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.